Objective responses observed from combination therapy in subjects previously refractory to anti-PD1 therapy; 2/2 responders in late-line RCC, 1 responder with heavily pretreated CCA (tumors generally not responsive to anti-PD1 alone). Here, PDCD1 is linked to cholangiocarcinoma.